Keywords: Roche, Financial results, 2012
Roche sees strong 2012 performance in USA but slowdown in Europe
Article | 31 January 2013
Swiss drug major Roche (ROG: SIX) has reported 2012 financial results with 4% growth in group sales to 45.5 billion Swiss francs ($49.29 billion), ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
